Benzinga's M&A Chatter for Tuesday April 12, 2016 - Bristol-Myers Squibb (NYSE:BMY)

The following are the M&A deals, rumors and chatter circulating on Wall Street for Tuesday April 12, 2016

Investor Group Apparently Bids $32/Share for IDT then Withdraws OfferThe Rumor

Shares of Integrated Device Technology Inc.

IDTI

spiked sharply higher on Tuesday, following the release of a 13D filing, showing an investor group, led by Nauman A. Aly was offering $32.00 per share for the shares of IDTI they did not already own. After shares hit a high of $23.99, some traders became suspicious of the filing, thinking it was another hoax, similar to the one perputr . An investigation by

Benzinga

failed to turn up Mr. Aly, who provided an office address in Portland, Oregon. An amended 13D was released soon after, which omitted any mention of the offer, but did show that Mr. Aly had sold "American-style call options referencing 185,000 shares of Common Stock for an aggregate consideration of $447,740". Those calls were purchased for a total of $19,966. Integrated Device Technology declined comment on the offer, but said they would issue a response. Integrated Device Technology closed at $20.22 on Tuesday, up 4%.

Market Chatter of Potential Mondelez Bid for General MillsThe Rumor

General Mills

GIS

rose Tuesday, on market chatter circulating on Twitter of a potential bid from Mondelez International

MDLZ

. Spokespersons for General Mills and Mondelez did not respond to requests for comment. General Mills closed at $63.46 on Tuesday, up $0.58.

Unconfirmed Market Chatter of Potential Celgene Merger with Bristol Myers SquibbThe Rumor

Shares of Celgene Corp

CELG

and Bristol Myers Squibb

BMY

, rose Tuesday on renewed market chatter of a potential merger of the two pharma companies. A similar rumor surfaced in February. Spokespersons for Celgene and Bristol Myers did not respond to requests for comment. Celgene closed at $105.26 on Tuesday, up 1.40%. BMY rose 1.3%, closing at $66.84.

Medivation Said to have Rebuffed Takeover Approach from SanofiThe Rumor

Medivation Inc.

MDVN

is said to have spurned recent takeover approach from France's Sanofi

SNY

, according to sources as reported by

Bloomberg

on Tuesday. Sanofi wants Medivation's treatments for hard-to-cure cancers, the sources said. Spokespersons for Medivation and Sanofi declined comment. Medivation closed at $45.73 on Tuesday, up 1.08% and traded around $50.00 after-hours.

Market News and Data brought to you by Benzinga APIs